Coya Therapeutics, Inc. (NASDAQ:COYA) Short Interest Update

Coya Therapeutics, Inc. (NASDAQ:COYA) was the recipient of a significant increase in short interest in the month of October. As of October 31st, there was short interest totalling 196,500 shares, an increase of 5.6% from the October 15th total of 186,100 shares. Based on an average daily trading volume, of 77,200 shares, the days-to-cover ratio is presently 2.5 days. Approximately 1.4% of the company’s shares are short sold.

Insider Buying and Selling at Coya Therapeutics

In other Coya Therapeutics news, CEO Arun Swaminathan acquired 5,000 shares of the company’s stock in a transaction on Monday, November 11th. The shares were purchased at an average cost of $7.34 per share, with a total value of $36,700.00. Following the completion of the purchase, the chief executive officer now owns 5,000 shares of the company’s stock, valued at approximately $36,700. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Over the last three months, insiders have acquired 9,510 shares of company stock valued at $69,615. 9.80% of the stock is currently owned by company insiders.

Institutional Trading of Coya Therapeutics

Institutional investors have recently modified their holdings of the business. Vanguard Group Inc. boosted its holdings in shares of Coya Therapeutics by 772.3% in the first quarter. Vanguard Group Inc. now owns 847,490 shares of the company’s stock worth $8,407,000 after acquiring an additional 750,338 shares during the period. Renaissance Technologies LLC purchased a new position in Coya Therapeutics during the 2nd quarter valued at about $101,000. GHP Investment Advisors Inc. bought a new stake in shares of Coya Therapeutics during the third quarter valued at about $169,000. Gilbert & Cook Inc. purchased a new stake in shares of Coya Therapeutics in the second quarter worth about $61,000. Finally, Geode Capital Management LLC boosted its position in shares of Coya Therapeutics by 3.3% in the third quarter. Geode Capital Management LLC now owns 142,309 shares of the company’s stock valued at $918,000 after acquiring an additional 4,485 shares during the period. 39.75% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on COYA. Chardan Capital reissued a “buy” rating and issued a $14.00 price objective on shares of Coya Therapeutics in a research note on Thursday, November 7th. HC Wainwright reissued a “buy” rating and issued a $18.00 price target on shares of Coya Therapeutics in a research report on Monday, November 11th.

Coya Therapeutics Price Performance

Shares of NASDAQ COYA remained flat at $6.07 during midday trading on Tuesday. The stock had a trading volume of 70,365 shares, compared to its average volume of 71,783. The firm has a market cap of $101.43 million, a PE ratio of -9.35 and a beta of 0.46. The firm has a 50-day moving average price of $7.12 and a 200 day moving average price of $6.95. Coya Therapeutics has a 12-month low of $4.75 and a 12-month high of $10.69.

Coya Therapeutics (NASDAQ:COYA) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.41) by $0.15. On average, equities analysts anticipate that Coya Therapeutics will post -1.15 EPS for the current fiscal year.

About Coya Therapeutics

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.